These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 12402604)
1. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Yamamoto R; Nakayama M; Hasegawa T; Miwako N; Yamamoto H; Yokoyami K; Ikeda M; Kato N; Hayakawa H; Takahashi H; Otsuka Y; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():131-4. PubMed ID: 12402604 [TBL] [Abstract][Full Text] [Related]
2. [Long-standing high-transport membrane as a risk factor for EPS development after PD withdrawal: an analysis based on changes in peritoneal function during and after CAPD withdrawal]. Nakayama M; Ikeda M; Katoh N; Hayakawa H; Numata M; Otsuka Y; Yamamoto R; Yamamoto H; Yokoyama K; Kubo H; Kawaguchi Y; Hosoya T Nihon Jinzo Gakkai Shi; 2002 May; 44(4):396-401. PubMed ID: 12073625 [TBL] [Abstract][Full Text] [Related]
3. Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002. Nakayama M; Yamamoto H; Ikeda M; Hasegawa T; Kato N; Takahashi H; Otsuka Y; Yokoyama K; Yamamoto R; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():144-8. PubMed ID: 12402607 [TBL] [Abstract][Full Text] [Related]
4. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis. Moriishi M; Kawanishi H Adv Perit Dial; 2008; 24():56-9. PubMed ID: 18986002 [TBL] [Abstract][Full Text] [Related]
5. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Yamamoto H; Nakayama M; yamamoto R; Otsuka Y; Takahashi H; Kato N; Hayakawa H; Hasegawa T; Ikeda M; Yokoyama K; Kawaguchi Y; Mukai H; Hosoya T Adv Perit Dial; 2002; 18():135-8. PubMed ID: 12402605 [TBL] [Abstract][Full Text] [Related]
7. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Otsuka Y; Nakayama M; Ikeda M; Sherif AM; Yokoyama K; Yamamoto H; Kawaguchi Y Clin Exp Nephrol; 2005 Dec; 9(4):315-319. PubMed ID: 16362159 [TBL] [Abstract][Full Text] [Related]
8. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients. Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934 [TBL] [Abstract][Full Text] [Related]
9. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N Adv Perit Dial; 2002; 18():149-53. PubMed ID: 12402608 [TBL] [Abstract][Full Text] [Related]
10. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis. La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295 [TBL] [Abstract][Full Text] [Related]
11. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan. Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369 [TBL] [Abstract][Full Text] [Related]
12. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of the dialysis adequacy and transport test in peritoneal dialysis. Seo JJ; Kim YL; Park SH; Kim CD; Kim JC; Jang MH; Choi HJ Adv Perit Dial; 2005; 21():25-30. PubMed ID: 16686280 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes of peritoneal function calculated by personal dialysis capacity in a patient after long-term continuous ambulatory peritoneal dialysis. Nakamoto H; Takane H; Sugahara S; Kanno Y; Okada H; Yamamoto T; Suzuki H Adv Perit Dial; 2003; 19():97-102. PubMed ID: 14763042 [TBL] [Abstract][Full Text] [Related]
15. Peritoneal dialysis patients with high effluent fibrin degradation products. Moriishi M; Kawanishi H; Tsuchiya S Adv Perit Dial; 2009; 25():41-4. PubMed ID: 19886315 [TBL] [Abstract][Full Text] [Related]
16. Differences in peritoneal equilibration test results in patients aged above or below 60 years. Grzegorzewska AE; Leander M; Mariak I Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583 [TBL] [Abstract][Full Text] [Related]
17. Two years on continuous ambulatory peritoneal dialysis--does it change peritoneal transport? Kaczmarek EE; Grzegorzewska AE Adv Perit Dial; 2004; 20():2-7. PubMed ID: 15384785 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis. Twardowski ZJ; Moore HL; Prowant BF; Satalowich R Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338 [TBL] [Abstract][Full Text] [Related]